Rifaximin

ANDA 213713, held by Sandoz Inc. Rifaximin.

As of Nov 15, 2026, ANDA 213713 (Rifaximin), held by Sandoz Inc, was not approved, with 0 approved supplements and 0 published complete response letters.

• First approved: Not approved
• Supplements approved: 0
• Complete response letters: 0

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters